Detailed description page of B3Pdb
This page provides detail information of Selected ID b3pdb_0049 |
| Primary information | |
|---|---|
| B3PDB ID | b3pdb_0049 |
| Peptide Name | gH625Cys |
| PEPTIDE SEQUENCE (1-letter) | HGLASTLTRWAHYNALIRAF |
| PEPTIDE SEQUENCE (3-letter) | HisGlyLeuAlaSerThrLeuThrArgTrpAlaHisTyrAsnAlaLeuIleArgAlaPhe |
| N-terminal modification | Acetylaed at N-terminal |
| C-terminal modification | Cys-CONH2 group is attached at C-terminal |
| Chemical modification | NA |
| Peptide Length | 21 |
| Conformation | Linear |
| Peptide Nature | NA |
| Source/Origin of peptide | Chemically synthesized |
| SMILES | N[C@@]([H])(CC1=CN=C-N1)C(=O)NCC(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(=CN2)C1=C2C=CC=C1)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)O |
| Cell Line | BMECs |
| In vitro CONCENTRATION | 5 micromolar |
| In vitro METHOD | Fluorescence microscopy |
| In vitro RESULT | Liposomes preparations were non-toxic for the endothelial cells and improves the transfer of liposom |
| ANIMAL MODEL | Mouse |
| In vivo CONCENTRATION | NA |
| In vivo MODE OF DELIVERY | Intravenous |
| In vivo METHOD | Fluorescence microscopy |
| In vivo RESULT | gH625 ameliorates the efficiency of liposomes to deliver. PACAP |
| ACTION | gH625-liposomes represent a promising strategy to deliver therapeutic agents to CNS and to provide a |
| TRANSPORT TYPE | NA |
| SUBCELLULAR LOCALISATION | NA |
| COMBINATION | Comined with liposome |
| PHYSICAL CONDITION | NA |
| RESPONSE | NA |
| RESULT | NA |
| LABEL | NA |
| PMID | 31235716 |